![IMD-Pharma uncovers the mechanism of action of its new asset in Rheumatoid Arthritis.](https://www.imd-pharma.com/wp-content/uploads/2023/06/image-3-candidats-pipeline.jpg)
![IMD-Pharma uncovers the mechanism of action of its new asset in Rheumatoid Arthritis.](https://www.imd-pharma.com/wp-content/uploads/2023/06/image-3-candidats-pipeline.jpg)
![IMD-Pharma signs a joint research agreement with the Inserm research unit U1291 (Infinity, PACID team, Toulouse).](https://www.imd-pharma.com/wp-content/uploads/2023/06/inserm-infinity-1080x675.webp)
IMD-Pharma signs a joint research agreement with the Inserm research unit U1291 (Infinity, PACID team, Toulouse).
![IMD-Pharma validates in vitro and in vivo a new lead for Rheumatoid Arthritis.](https://www.imd-pharma.com/wp-content/uploads/2023/06/rhumatoid-arthritis-1080x675.webp)
IMD-Pharma validates in vitro and in vivo a new lead for Rheumatoid Arthritis.
![IMD-Pharma hires Zakari Mouheb (biology), Laëtitia Lüdge (formulation) and Anthony Augé (chemistry) as apprentices in Master (12 months contract).](https://www.imd-pharma.com/wp-content/uploads/2023/06/welcome-1080x675.webp)
IMD-Pharma hires Zakari Mouheb (biology), Laëtitia Lüdge (formulation) and Anthony Augé (chemistry) as apprentices in Master (12 months contract).
![IMD-Pharma signs a joint research agreement with the CNRS research unit UMR 5623 (IMRCP, SMODD team, Toulouse).](https://www.imd-pharma.com/wp-content/uploads/2023/06/imrcp-1080x675.webp)